Annual Cash & Cash Equivalents
$135.82 M
+$792.00 K+0.59%
December 31, 2023
Summary
- As of February 7, 2025, VNDA annual cash & cash equivalents is $135.82 million, with the most recent change of +$792.00 thousand (+0.59%) on December 31, 2023.
- During the last 3 years, VNDA annual cash & cash equivalents has risen by +$74.79 million (+122.54%).
- VNDA annual cash & cash equivalents is now -61.85% below its all-time high of $356.00 million, reached on December 1, 1997.
Performance
VNDA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$100.50 M
-$2.46 M-2.39%
September 30, 2024
Summary
- As of February 7, 2025, VNDA quarterly cash and cash equivalents is $100.50 million, with the most recent change of -$2.46 million (-2.39%) on September 30, 2024.
- Over the past year, VNDA quarterly cash and cash equivalents has dropped by -$24.66 million (-19.70%).
- VNDA quarterly cash and cash equivalents is now -71.62% below its all-time high of $354.17 million, reached on March 31, 2023.
Performance
VNDA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
VNDA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +0.6% | -19.7% |
| 3 y3 years | +122.5% | -19.7% |
| 5 y5 years | +122.6% | -19.7% |
VNDA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +160.8% | -71.6% | +103.5% |
| 5 y | 5-year | at high | +201.3% | -71.6% | +123.0% |
| alltime | all time | -61.9% | +735.3% | -71.6% | +702.7% |
Vanda Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $100.50 M(-2.4%) |
| Jun 2024 | - | $102.95 M(-17.7%) |
| Mar 2024 | - | $125.16 M(-7.9%) |
| Dec 2023 | $135.82 M(+0.6%) | $135.82 M(-25.9%) |
| Sep 2023 | - | $183.19 M(+22.1%) |
| Jun 2023 | - | $150.03 M(-57.6%) |
| Mar 2023 | - | $354.17 M(+162.3%) |
| Dec 2022 | $135.03 M(+159.3%) | $135.03 M(+173.4%) |
| Sep 2022 | - | $49.40 M(-15.2%) |
| Jun 2022 | - | $58.23 M(-13.0%) |
| Mar 2022 | - | $66.93 M(+28.5%) |
| Dec 2021 | $52.07 M(-14.7%) | $52.07 M(+3.1%) |
| Sep 2021 | - | $50.52 M(-11.7%) |
| Jun 2021 | - | $57.24 M(-20.6%) |
| Mar 2021 | - | $72.13 M(+18.2%) |
| Dec 2020 | $61.03 M(+35.4%) | $61.03 M(+7.1%) |
| Sep 2020 | - | $56.97 M(-40.2%) |
| Jun 2020 | - | $95.31 M(+46.7%) |
| Mar 2020 | - | $64.95 M(+44.1%) |
| Dec 2019 | $45.07 M(-26.1%) | $45.07 M(+15.0%) |
| Sep 2019 | - | $39.21 M(-15.8%) |
| Jun 2019 | - | $46.54 M(+35.4%) |
| Mar 2019 | - | $34.38 M(-43.6%) |
| Dec 2018 | $61.01 M(+81.4%) | $61.01 M(+0.4%) |
| Sep 2018 | - | $60.78 M(-0.2%) |
| Jun 2018 | - | $60.89 M(-60.8%) |
| Mar 2018 | - | $155.29 M(+361.8%) |
| Dec 2017 | $33.63 M(-16.8%) | $33.63 M(+48.9%) |
| Sep 2017 | - | $22.59 M(+58.7%) |
| Jun 2017 | - | $14.23 M(-29.2%) |
| Mar 2017 | - | $20.11 M(-50.3%) |
| Dec 2016 | $40.43 M(-20.5%) | $40.43 M(+23.4%) |
| Sep 2016 | - | $32.77 M(+41.3%) |
| Jun 2016 | - | $23.19 M(-40.1%) |
| Mar 2016 | - | $38.74 M(-23.8%) |
| Dec 2015 | $50.84 M(-16.5%) | $50.84 M(+8.7%) |
| Sep 2015 | - | $46.79 M(-3.2%) |
| Jun 2015 | - | $48.34 M(+47.3%) |
| Mar 2015 | - | $32.81 M(-46.1%) |
| Dec 2014 | $60.90 M(-6.0%) | $60.90 M(+297.8%) |
| Sep 2014 | - | $15.31 M(-9.9%) |
| Jun 2014 | - | $16.99 M(-60.7%) |
| Mar 2014 | - | $43.26 M(-33.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2013 | $64.76 M(-27.0%) | $64.76 M(-54.4%) |
| Sep 2013 | - | $142.17 M(+37.2%) |
| Jun 2013 | - | $103.63 M(-5.7%) |
| Mar 2013 | - | $109.93 M(+23.8%) |
| Dec 2012 | $88.77 M(+1.0%) | $88.77 M(-15.1%) |
| Sep 2012 | - | $104.52 M(+10.7%) |
| Jun 2012 | - | $94.39 M(-12.7%) |
| Mar 2012 | - | $108.09 M(+22.9%) |
| Dec 2011 | $87.92 M(+106.6%) | $87.92 M(+45.7%) |
| Sep 2011 | - | $60.33 M(+19.7%) |
| Jun 2011 | - | $50.39 M(-4.1%) |
| Mar 2011 | - | $52.52 M(+23.4%) |
| Dec 2010 | $42.56 M(-79.3%) | $42.56 M(-58.5%) |
| Sep 2010 | - | $102.47 M(-29.6%) |
| Jun 2010 | - | $145.65 M(-14.3%) |
| Mar 2010 | - | $169.95 M(-17.2%) |
| Dec 2009 | $205.29 M(+425.3%) | $205.29 M(+1078.7%) |
| Sep 2009 | - | $17.42 M(-27.5%) |
| Jun 2009 | - | $24.01 M(-29.0%) |
| Mar 2009 | - | $33.83 M(-13.4%) |
| Dec 2008 | $39.08 M(-6.8%) | $39.08 M(-5.7%) |
| Sep 2008 | - | $41.44 M(-26.7%) |
| Jun 2008 | - | $56.50 M(+0.9%) |
| Mar 2008 | - | $56.02 M(+33.6%) |
| Dec 2007 | $41.93 M(+35.6%) | $41.93 M(-30.1%) |
| Sep 2007 | - | $59.95 M(+25.9%) |
| Jun 2007 | - | $47.63 M(-25.8%) |
| Mar 2007 | - | $64.22 M(+107.6%) |
| Dec 2006 | $30.93 M(+47.2%) | $30.93 M(-3.0%) |
| Sep 2006 | - | $31.90 M(-31.3%) |
| Jun 2006 | - | $46.44 M(+270.9%) |
| Mar 2006 | - | $12.52 M(-40.4%) |
| Dec 2005 | $21.01 M(+29.2%) | $21.01 M |
| Dec 2004 | $16.26 M(-94.9%) | - |
| Dec 2003 | $320.54 M(+54.0%) | - |
| Dec 2002 | $208.20 M(-21.6%) | - |
| Dec 2001 | $265.58 M(+93.9%) | - |
| Dec 2000 | $136.99 M(+21.7%) | - |
| Dec 1999 | $112.60 M(-32.9%) | - |
| Dec 1998 | $167.80 M(-52.9%) | - |
| Dec 1997 | $356.00 M(+296.9%) | - |
| Dec 1996 | $89.70 M(+369.6%) | - |
| Dec 1995 | $19.10 M(-19.1%) | - |
| Dec 1994 | $23.60 M | - |
FAQ
- What is Vanda Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Vanda Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Vanda Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of VNDA is $135.82 M
What is the all time high annual cash & cash equivalents for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high annual cash & cash equivalents is $356.00 M
What is Vanda Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, VNDA annual cash & cash equivalents has changed by +$792.00 K (+0.59%)
What is Vanda Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of VNDA is $100.50 M
What is the all time high quarterly cash and cash equivalents for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high quarterly cash and cash equivalents is $354.17 M
What is Vanda Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, VNDA quarterly cash and cash equivalents has changed by -$24.66 M (-19.70%)